Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW). Available at: https://clinicaltrials.gov/ct2/show/NCT03037385 - ClinicalTrials.gov